Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

163.37USD
17 Feb 2017
Change (% chg)

$2.07 (+1.28%)
Prev Close
$161.30
Open
$161.30
Day's High
$163.46
Day's Low
$161.12
Volume
892,449
Avg. Vol
1,505,613
52-wk High
$186.88
52-wk Low
$119.37

Latest Key Developments (Source: Significant Developments)

Illumina says Novaseq's S1, S4 flow cells expected to be available for shipment in Q3 2017
Monday, 13 Feb 2017 07:50am EST 

Illumina Inc : Illumina Inc- Novaseq's S1 and S4 flow cells have been prioritized and are expected to be available for shipment in Q3 of 2017 - SEC filing . Illumina Inc- Novaseq 5000 system and S3 flow cells are expected to be available for shipment in early 2018 - SEC filing . Illumina Inc- Novaseq 6000 system and S2 flow cells remain on track for shipment late in Q1 of this year - SEC filing Source: (http://bit.ly/2kKESiN) Further company coverage: [ILMN.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Illumina Q4 non-gaap earnings per share $0.85
Tuesday, 31 Jan 2017 04:05pm EST 

Illumina Inc : Illumina reports full financial results for fourth quarter and fiscal year 2016 . Q4 non-gaap earnings per share $0.85 . Q4 gaap earnings per share $0.84 . Q4 earnings per share view $0.82 -- Thomson Reuters I/B/E/S . Sees FY 2017 non-gaap earnings per share $3.60 to $3.70 . Sees q1 gaap earnings per share $0.51 to $0.56 . Sees FY 2017 revenue up 10 to 12 percent . Sees q1 revenue $580 million to $595 million . Q4 revenue $619 million versus I/B/E/S view $616.4 million . Q1 earnings per share view $0.80, revenue view $618.6 million -- Thomson Reuters I/B/E/S . Fy2017 earnings per share view $3.65, revenue view $2.65 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 gaap earnings per share $3.25 to $3.35 .Illumina Inc - sees q1 non-gaap earnings per diluted share attributable to illumina stockholders of $0.60 to $0.65.  Full Article

Illumina appoints Sam Samad as senior VP and CFO
Wednesday, 7 Dec 2016 06:30am EST 

Illumina Inc: Illumina extends management team, appoints Sam A. Samad as senior vice president and chief financial officer .Sam A. Samad will join company on January 6, 2017.  Full Article

Illumina increases size of board from eight to nine members
Thursday, 28 Jul 2016 04:30pm EDT 

Illumina Inc : Effective as of july 27, 2016, board of directors increased size of board from eight to nine members - sec filing Further company coverage: [ILMN.O] (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Illumina reports Q2 adj. earnings $0.86/shr
Tuesday, 26 Jul 2016 04:05pm EDT 

Illumina Inc : Illumina reports financial results for second quarter of fiscal year 2016 . Q2 non-GAAP earnings per share $0.86 . Q2 GAAP earnings per share $0.82 . Sees Q3 2016 revenue $625 million to $630 million . Q2 revenue $600 million versus I/B/E/S view $593.1 million . Sees FY 2016 non-GAAP earnings per share $3.48 to $3.58 . Sees FY 2016 revenue up about 12 percent .Q2 earnings per share view $0.73 -- Thomson Reuters I/B/E/S.  Full Article

Enzo Biochem says Enzo Life Sciences reached settlement with Illumina that included payment of $21 mln to Enzo
Thursday, 7 Jul 2016 08:01am EDT 

Enzo Biochem Inc : Co's unit, Enzo Life Sciences, has reached and finalized a settlement with Illumina that included a payment of $21 million to enzo . Settlement resolving dispute between Enzo Life Sciences and Illumina impacts only one of 11 cases originally brought by enzo .Settlement related to action brought in delaware court by Enzo alleging infringement of patent.  Full Article

Illumina received a product approval certificate for MiSeqDx instrument
Monday, 9 May 2016 04:05pm EDT 

Illumina Inc :Received a product approval certificate for Miseqdx Instrument and Miseqdx universal kit with MFDS in South Korea.  Full Article

Illumina Files Patent Infringement Suit in Switzerland against Genoma SA
Thursday, 21 Apr 2016 04:05pm EDT 

Illumina:Says co and unit Verinata Health, Inc. (together "Illumina"), filed a patent infringement suit against Genoma SA in the Federal Patent Court in Switzerland.Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent (CH) 2 183 693 B1, European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and European Patent (CH) 2 514 842.The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT).Tranquility NIPT service uses the IONA(reg) Test sold by Premaitha Health plc. Illumina previously filed separate suits against Premaitha in the United Kingdom for sale of the IONA Test.  Full Article

Illumina Inc says Francis Desouza appointed president and CEO
Monday, 7 Mar 2016 04:05pm EST 

Illumina Inc:Says Jay Flatley to assume role of executive chairman of the board of directors of Illumina; Francis Desouza appointed president and CEO.Says Francis Desouza, currently president, will be appointed president and chief executive officer.  Full Article

Illumina sues Oxford Nanopore for Patent Infringement
Tuesday, 23 Feb 2016 04:05pm EST 

Illumina:That the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).The lawsuits were filed concurrently with the U.S. International Trade Commission and in the U.S. District Court for the Southern District of California.Illumina is seeking all available remedies.  Full Article

More From Around the Web

BRIEF-Illumina says Novaseq's S1, S4 flow cells expected to be available for shipment in Q3 2017

* Illumina Inc- Novaseq's S1 and S4 flow cells have been prioritized and are expected to be available for shipment in Q3 of 2017 - SEC filing